{
    "nct_id": "NCT05987956",
    "official_title": "Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.",
    "inclusion_criteria": "* 1. Clinical diagnosis of Non-Small Cell Lung Cancer (NSCLC)\n* 2. Clinical biopsy diagnosis of NSCLC\n* 3. Suitable for enough blood-drawing\n* 4. Random and double blind\n* 5. Measurable disease\n* 6. Adequate organ functions\n* 7. Adequate performance status\n* 8. Age 22 years old and over\n* 9. Sign an informed consent form\n* 10. Receive blood-drawing\nHealthy volunteers allowed\nMust have minimum age of 22 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* 1. Pneumonectomy\n* 2. Treatment with other anti-cancer therapies and cannot be stopped currently\n* 3. Pregnancy\n* 4. Breast-feeding\n* 5. The patients with other serious intercurrent illness or infectious diseases\n* 6. Have more than one different kind of cancer at the same time\n* 7. Serious Allergy to Drugs\n* 8. Serious Bleed Tendency\n* 9. Serious Risks or Serious Adverse Events of the drug product\n* 10. The prohibition of drug products\n* 11. Have no therapeutic effects\n* 12. Follow up to the most current label",
    "miscellaneous_criteria": "* Select 600 Non-Small Cell Lung Cancer Patients who are suitable for blood-drawing.\n* Dosage Duration at least 90 days\n* The usual approach group - Recruit 300 double blind random group separated NSCLC patients currently used the Chemotherapy NDC...01 on ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily, film coated after biopsy diagnosis, like as the usual approach group.\n* The study approach group - Recruit 300 double blind random group separated NSCLC patients currently used the Chemotherapy NDC...86 on ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily, film coated after biopsy diagnosis, like as the study approach group."
}